Healthcare / BiotechnologyBSE
$77.08
-1.10 (-1.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-91.4M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
908.8x
↑EV/EBITDA
19.5x
↑ROE
0.3%
↑Gross Margin
91.9%
↑Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.6%
FCF CAGR
—
FCF margin
-12.7%
FCF / Net income
-44.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $468.4M · net income $1.3M · FCF $-59.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $468.4M | $468.4M | $396.5M | $361.8M | $677.9M |
| Net Income | $1.3M | $1.3M | $-13.0M | $-30.5M | $119.4M |
| EBITDA | $72.9M | $72.9M | $51.9M | $24.1M | $226.3M |
| EPS | 0.08 | 0.08 | -0.84 | -1.99 | 7.81 |
| Gross Margin | 91.9% | 91.9% | 90.4% | 91.7% | 89.1% |
| Operating Margin | 2.8% | 2.8% | -3.1% | -10.3% | 20.4% |
| Net Margin | 0.3% | 0.3% | -3.3% | -8.4% | 17.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.41 | 0.41 | 0.28 | 0.21 | 0.25 |
| Cash Flow | |||||
| Free Cash Flow | $-59.6M | $-59.6M | $-91.4M | $-145.7M | $172.2M |
| Returns | |||||
| ROE | 0.3% | 0.3% | -2.7% | -6.3% | 23.6% |
| Valuation | |||||
| P/E | 908.77 | 908.77 | — | — | 19.43 |
| EV/EBITDA | 19.52 | 19.52 | 18.33 | 34.83 | 9.50 |
| P/B | 2.45 | 2.45 | 1.70 | 1.67 | 4.59 |
| Growth & Yield | |||||
| Revenue Growth | 18.1% | 18.1% | 9.6% | -46.6% | — |
| EPS Growth | 110.1% | 110.1% | 57.9% | -125.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
332.0%
EPS terminal req.
$6.84
Spread vs growth
-221.9%
5Y implied EPS CAGR
150.0%
EPS terminal req.
$8.28
Spread vs growth
-39.8%
10Y implied EPS CAGR
65.8%
EPS terminal req.
$13.33
Spread vs growth
44.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+96.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.84 → 0.08
Residual
+96.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.